Research Topic: psychedelics

Lysergic Acid Diethylamide (LSD) and the Heart: Exploring the Potential Impacts of LSD on Cardiovascular Function

This review examines how LSD affects the heart and blood vessels. While some evidence suggests LSD might protect against heart disease by reducing inflammation and blood clots, acute use can dangerously raise heart rate and blood pressure, and cause blood vessel constriction. Regular low-dose use raises concerns about potential valve damage. More research is needed to understand the full cardiovascular safety of LSD before it can be considered for medical use.

Read More »

Neuroprotective effects of psilocybin in a rat model of stroke

Scientists studied whether psilocybin, the active compound in magic mushrooms, could protect the brain from stroke damage in rats. They found that psilocybin reduced brain damage, improved movement and behavior recovery after stroke, and worked by increasing a protective brain chemical called BDNF. This research suggests psilocybin could become a new treatment for stroke patients, especially since stroke often leads to depression and anxiety, which psilocybin may also help treat.

Read More »

Psilocybin’s effects on cognition and creativity: A scoping review

This comprehensive review examines how psilocybin affects thinking abilities and creativity. Researchers found that large doses initially impair mental performance during the experience, but small doses may enhance creativity. Importantly, the cognitive effects appear to improve after the acute effects wear off, suggesting initial impairment doesn’t cause lasting damage. The review emphasizes the need for more rigorous long-term studies to better understand psilocybin’s effects on brain function.

Read More »

Sex-specific effects of psychedelic drug exposure on central amygdala reactivity and behavioral responding

Researchers studied how psilocybin’s active form affects the brain’s fear center in both male and female rats. They found that a single dose produced different effects in males versus females, with males showing lasting reductions in fear responses over 28 days while females showed variable changes. These findings help explain why psychedelics might work differently between sexes and could inform how they’re used to treat anxiety and depression in humans.

Read More »

Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects

This study examined whether taking the antidepressant escitalopram before using psilocybin affects the drug’s effects. Twenty-three healthy participants took either escitalopram or placebo for two weeks, then received a dose of psilocybin. Surprisingly, escitalopram did not reduce the positive mood effects of psilocybin and actually reduced some negative side effects like anxiety and bad feelings. The combination appeared safe with no increased cardiovascular risks.

Read More »

Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology

This comprehensive study analyzed three classic psychedelic drugs—LSD, psilocybin (from magic mushrooms), and DMT—across three levels: how people experience them, how they affect brain activity, and how they interact with brain receptors. Researchers found that LSD produces more intense visual experiences than psilocybin, and all three drugs significantly alter brain connectivity patterns. The study highlights the importance of standardizing research methods to better understand how these compounds might help treat depression and addiction.

Read More »

Associations between psychedelic-related and meditation-related variables: A longitudinal study

This study of over 13,000 people examined how using psychedelics relates to meditation practices. Researchers found that people who used psychedelics during the study period increased their meditation practice more than those who didn’t. Importantly, people who already had higher levels of mindfulness and self-compassion before using psychedelics had less difficult experiences during their use. However, among people who were already meditating regularly, psychedelic use was linked to more difficulties during meditation.

Read More »

Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis

This study compared psychedelic drugs (psilocybin, LSD, MDMA, ayahuasca) with the antidepressant escitalopram for treating depression. Researchers analyzed 19 clinical trials and found that while psilocybin showed promise, its actual effectiveness was smaller than previously reported due to blinding issues in earlier studies. High-dose psilocybin performed better than escitalopram in some comparisons, but had a similar small effect size to current antidepressants.

Read More »

Premorbid characteristics of the SAPAP3 mouse model of obsessive-compulsive disorder: behavior, neuroplasticity, and psilocybin treatment

This research examined young genetically modified mice that lack the SAPAP3 gene to understand early signs of obsessive-compulsive disorder-like behavior. The study found that these juvenile mice showed anxiety-like behaviors before developing the excessive grooming typical of the adult model. Surprisingly, psilocybin treatment—which works in adult mice—did not help reduce anxiety in the younger mice, suggesting that the brain needs to mature for this treatment to be effective.

Read More »

Social pain: A systematic review on interventions

This study reviews different treatments for social pain—the emotional hurt from rejection and social exclusion. Researchers found that regular pain reliever acetaminophen, mindfulness meditation, and the psychedelic compound psilocybin can reduce social pain, while placebo pills also help when people believe they work. Interestingly, combining acetaminophen with forgiveness works better than either alone, suggesting that both physical and emotional pain may use similar brain pathways.

Read More »
Scroll to Top